Literature DB >> 10189459

Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?

C K Kuhl1, P Mielcareck, S Klaschik, C Leutner, E Wardelmann, J Gieseke, H H Schild.   

Abstract

PURPOSE: To assess the relevance of the signal intensity time course for the differential diagnosis of enhancing lesions in dynamic magnetic resonance (MR) imaging of the breast.
MATERIALS AND METHODS: Two hundred sixty-six breast lesions were examined with a two-dimensional dynamic MR imaging series and subtraction postprocessing. Time-signal intensity curves of the lesions were obtained and classified according to their shapes as type I, which was steady enhancement; type II, plateau of signal intensity; or type III, washout of signal intensity. Enhancement rates and curve types of benign and malignant lesions were compared.
RESULTS: There were 101 malignant and 165 benign lesions. The distribution of curve types for breast cancers was type I, 8.9%; type II, 33.6%; and type III, 57.4%. The distribution of curve types for benign lesions was type I, 83.0%; type II, 11.5%; and type III, 5.5%. The distributions proved significantly different (chi 2 = 139.6; P < .001). The diagnostic indices for signal intensity time course were sensitivity, 91%; specificity, 83%; and diagnostic accuracy, 86%. The diagnostic indices for the enhancement rate were sensitivity, 91%; specificity, 37%; and diagnostic accuracy, 58%.
CONCLUSION: The shape of the time-signal intensity curve is an important criterion in differentiating benign and malignant enhancing lesions in dynamic breast MR imaging. A type III time course is a strong indicator of malignancy and is independent of other criteria.

Entities:  

Mesh:

Year:  1999        PMID: 10189459     DOI: 10.1148/radiology.211.1.r99ap38101

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  273 in total

1.  A use of a neural network to evaluate contrast enhancement curves in breast magnetic resonance images.

Authors:  D Vergnaghi; A Monti; E Setti; R Musumeci
Journal:  J Digit Imaging       Date:  2001-06       Impact factor: 4.056

2.  Breast magnetic resonance imaging: a computer-based analysis of enhancement curves.

Authors:  E Setti; G Trecate; M Ferrari; L Mainardi; R Musumeci
Journal:  J Digit Imaging       Date:  2001-06       Impact factor: 4.056

3.  [Suspected contrast medium concentration in dynamic MR-mammography. Post-traumatic fracture of the ribs].

Authors:  A Fink; K Wasser; D Aufderstrasse; H Ludemann; S Delorme
Journal:  Radiologe       Date:  2002-09       Impact factor: 0.635

4.  Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features.

Authors:  A Surov; H-J Holzhausen; A Wienke; J Schmidt; C Thomssen; D Arnold; K Ruschke; R-P Spielmann
Journal:  Br J Radiol       Date:  2012-06       Impact factor: 3.039

5.  Inflammatory breast carcinoma and locally advanced breast carcinoma: characterisation with MR imaging.

Authors:  V Girardi; G Carbognin; L Camera; F Bonetti; E Manfrin; G Pollini; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2010-10-06       Impact factor: 3.469

6.  [Importance of mammography, sonography and MRI for surveillance of neoadjuvant chemotherapy for locally advanced breast cancer].

Authors:  T Schlossbauer; M Reiser; K Hellerhoff
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

7.  Case of the season: a giant fibroadenoma in the guise of a phyllodes tumor; characterization role of MRI.

Authors:  Riham H El Khouli; Adeline Louie
Journal:  Semin Roentgenol       Date:  2009-04       Impact factor: 0.800

8.  Vascular perfusion of choroidal melanoma by 3.0 tesla magnetic resonance imaging.

Authors:  Bruce M Buerk; Jose S Pulido; Ignacio Chiong; Robert Folberg; Deepak P Edward; Mark T Duffy; Keith R Thulborn
Journal:  Trans Am Ophthalmol Soc       Date:  2004

9.  Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.

Authors:  Kenneth E Pengel; Bas B Koolen; Claudette E Loo; Wouter V Vogel; Jelle Wesseling; Esther H Lips; Emiel J Th Rutgers; Renato A Valdés Olmos; Marie Jeanne T F D Vrancken Peeters; Sjoerd Rodenhuis; Kenneth G A Gilhuijs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-29       Impact factor: 9.236

10.  Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.

Authors:  David C Newitt; Sheye O Aliu; Neil Witcomb; Gal Sela; John Kornak; Laura Esserman; Nola M Hylton
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.